GlassScriptPhysician profile
Bethany A Haynes
NPI 1275899197
$3,894.98
in general payments reported to CMS, 2019-2025
29 companies · $780 in 2025
The $780 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $281 · 2021: $909 · 2022: $436 · 2023: $587 · 2024: $675 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,028.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $661.50 | 2020-2025 | |
| Lilly USA, LLC | $409.63 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceuticals, INC. | $301.78 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.47 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $213.73 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $166.54 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $84.13 | 2021-2023 | Trintellix |
| Abbvie INC. | $82.86 | 2021-2023 | |
| Axsome Therapeutics, INC. | $73.52 | 2024-2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $70.14 | 2022-2025 | Givlaari |
| Amgen INC. | $68.00 | 2019-2023 | Prolia, Evenity |
| Exact Sciences Corporation | $65.22 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $59.94 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $56.84 | 2021-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $49.06 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $44.38 | 2023-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $38.74 | 2024 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $24.96 | 2019-2021 | |
| Verrica Pharmaceuticals INC. | $23.60 | 2025 | Ycanth |
| Phathom Pharmaceuticals, INC. | $18.65 | 2025 | Voquezna |
| Astellas Pharma US INC | $16.28 | 2024 | Veozah |
| Allergan, INC. | $15.37 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.22 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $13.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.80 | 2022 | |
| Dermira, INC. | $13.77 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.